However, the number of HER2‐positive patients with breast cancer contained in this microarray was only nine (6.4% of 140 cases), which was significantly lower than that in the epidemiological study.35 Therefore, it was essential for us to further verify the overexpression of FLI‐1 in the HER2‐positive subtype. This evidence concerns the gene FLI1 and breast carcinoma.